Bysanti and Nereus approvals outlined for Vanda
Vanda says two new drugs, NEREUS and BYSANTI, have been approved, with BYSANTI’s launch expected by year-end and plans to support revenue growth via patient switching and further phase III milestones.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.